34,015 Shares in Pliant Therapeutics, Inc. $PLRX Acquired by Catalyst Funds Management Pty Ltd

Catalyst Funds Management Pty Ltd bought a new stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 34,015 shares of the company’s stock, valued at approximately $39,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PLRX. Cormorant Asset Management LP purchased a new stake in shares of Pliant Therapeutics during the 1st quarter worth $4,050,000. Woodline Partners LP lifted its position in shares of Pliant Therapeutics by 1,875.0% during the first quarter. Woodline Partners LP now owns 2,514,084 shares of the company’s stock valued at $3,394,000 after buying an additional 2,386,789 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Pliant Therapeutics in the 1st quarter valued at about $1,642,000. Peapod Lane Capital LLC grew its position in shares of Pliant Therapeutics by 39.2% in the 2nd quarter. Peapod Lane Capital LLC now owns 893,730 shares of the company’s stock worth $1,037,000 after buying an additional 251,537 shares during the last quarter. Finally, Monaco Asset Management SAM purchased a new position in shares of Pliant Therapeutics in the 2nd quarter worth approximately $815,000. 97.30% of the stock is currently owned by hedge funds and other institutional investors.

Pliant Therapeutics Price Performance

NASDAQ PLRX opened at $1.55 on Friday. The company has a market cap of $95.25 million, a price-to-earnings ratio of -0.54 and a beta of 1.41. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.94 and a quick ratio of 13.93. The stock’s fifty day moving average price is $1.59 and its 200 day moving average price is $1.51. Pliant Therapeutics, Inc. has a 1 year low of $1.10 and a 1 year high of $15.80.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.10. As a group, equities research analysts forecast that Pliant Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PLRX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Wednesday, October 8th. Citigroup reissued a “neutral” rating on shares of Pliant Therapeutics in a research report on Sunday, August 10th. Piper Sandler dropped their target price on Pliant Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Wall Street Zen upgraded Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of Pliant Therapeutics in a research note on Friday, October 10th. One analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $3.93.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.